These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23212944)

  • 1. Insufficient reporting on race and ethnicity in randomized trials for patients with rheumatoid arthritis: comment on the article by Simsek et al.
    Potter J; Spruill T; Greenberg JD
    Arthritis Care Res (Hoboken); 2013 Apr; 65(4):666. PubMed ID: 23212944
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral glucocorticoids should be included in any recommendation for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: comment on the article by Singh et al.
    Conn DL
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1622-3; author reply 1623-4. PubMed ID: 23024030
    [No Abstract]   [Full Text] [Related]  

  • 3. Level of the indication of biologic agents in the 2012 American College of Rheumatology recommendations for the treatment of rheumatoid arthritis: comment on the article by Singh et al.
    Graudal N; Jürgens G
    Arthritis Care Res (Hoboken); 2013 May; 65(5):832. PubMed ID: 23097263
    [No Abstract]   [Full Text] [Related]  

  • 4. American College of Rheumatology treatment guidelines continue to omit guidance on glucocorticoids: comment on the article by Singh et al.
    Boers M; Kirwan JR; Bijlsma JW
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1622. PubMed ID: 22740377
    [No Abstract]   [Full Text] [Related]  

  • 5. Eligibility of rheumatoid arthritis patients seen in clinical practice for rheumatoid arthritis clinical trials: comment on the article by Sokka and Pincus.
    Yazici Y; Erkan D
    Arthritis Rheum; 2003 Dec; 48(12):3611; author reply 3613-5. PubMed ID: 14674017
    [No Abstract]   [Full Text] [Related]  

  • 6. Under-reporting of socio-economic status in randomized control trials of biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis.
    Chiu H; Hollingworth S; Van Driel M; Magin P; Benham H
    Rheumatology (Oxford); 2017 Apr; 56(4):660-661. PubMed ID: 28039418
    [No Abstract]   [Full Text] [Related]  

  • 7. Definition of rheumatoid arthritis remission in clinical practice: comment on the article by Felson et al.
    Block SR
    Arthritis Rheum; 2011 Nov; 63(11):3642; author's reply 3644. PubMed ID: 21792824
    [No Abstract]   [Full Text] [Related]  

  • 8. The British Society for Rheumatology Biologics Register: 6 years on.
    Hyrich KL; Watson KD; Isenberg DA; Symmons DP;
    Rheumatology (Oxford); 2008 Oct; 47(10):1441-3. PubMed ID: 18596052
    [No Abstract]   [Full Text] [Related]  

  • 9. Hypogammaglobulinemia in rheumatoid arthritis patients treated with rituximab: should we switch biologics? Comment on the article by Fraenkel et al.
    Evangelatos G; Moschopoulou M; Iliopoulos A; Fragoulis GE
    Arthritis Rheumatol; 2022 Jan; 74(1):174-175. PubMed ID: 34347942
    [No Abstract]   [Full Text] [Related]  

  • 10. Adherence to biologic DMARD therapies in rheumatoid arthritis.
    Koncz T; Pentek M; Brodszky V; Ersek K; Orlewska E; Gulacsi L
    Expert Opin Biol Ther; 2010 Sep; 10(9):1367-78. PubMed ID: 20681888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical contrasts with the American College of Rheumatology/European League Against Rheumatism provisional definitions of remission in rheumatoid arthritis for clinical trials: Comment on the article by Felson et al.
    Rotar Z; Praprotnik S; Tomšič M
    Arthritis Rheum; 2011 Nov; 63(11):3642-3; author's reply 3644. PubMed ID: 21792830
    [No Abstract]   [Full Text] [Related]  

  • 12. Response to: 'Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required' by Moots et al.
    Emery P; Vencovský J; Ghil J
    Ann Rheum Dis; 2016 May; 75(5):e25. PubMed ID: 26888947
    [No Abstract]   [Full Text] [Related]  

  • 13. Drugs for rheumatoid arthritis.
    Med Lett Drugs Ther; 2014 Dec; 56(1458):127-32. PubMed ID: 25519024
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic targets for rheumatoid arthritis.
    Keystone EC; Haraoui B
    J Rheumatol Suppl; 2009 Jun; 82():1. PubMed ID: 19509323
    [No Abstract]   [Full Text] [Related]  

  • 15. Rheumatoid arthritis.
    Lorenzo M
    Foot Ankle Clin; 2007 Sep; 12(3):525-37, vii. PubMed ID: 17765843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trials in rheumatoid arthritis: choosing the right outcome measures--comment on the article by Felson et al.
    Porter D
    Ann Rheum Dis; 2008 Sep; 67(9):1356. PubMed ID: 18697785
    [No Abstract]   [Full Text] [Related]  

  • 17. The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: where the rubber meets the road.
    Bathon JM; Cohen SB
    Arthritis Rheum; 2008 Jun; 59(6):757-9. PubMed ID: 18512712
    [No Abstract]   [Full Text] [Related]  

  • 18. Failure to report previously used drugs and dosages in pharmaceutical company-sponsored rheumatoid arthritis trials: comment on the article by Yocum et al.
    Parker CT; Rennie T
    Arthritis Rheum; 2004 Sep; 50(9):3051; author reply 3051-2. PubMed ID: 15457479
    [No Abstract]   [Full Text] [Related]  

  • 19. Applying science in practice: the optimization of biological therapy in rheumatoid arthritis.
    Ramiro S; Machado P; Singh JA; Landewé RB; da Silva JA
    Arthritis Res Ther; 2010; 12(6):220. PubMed ID: 21067530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rheumatoid arthritis: Missed opportunities in the 2015 ACR guideline for RA treatment.
    van Vollenhoven R
    Nat Rev Rheumatol; 2016 Mar; 12(3):135-6. PubMed ID: 26763731
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.